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Biological drugs are expensive, but can reduce symptoms 
and increase quality of life for patients with psoriasis. 
The aim of this study was to examine quality of life, di-
sease severity and treatment satisfaction in Danish, Fin-
nish and Swedish patients with psoriasis. Based on 12 
months’ data from patient surveys and chart reviews, 3 
treatment groups were identified: topical, systemic and/
or biological < 12 months, and biological for 12 months. 
Regression analyses were performed to investigate in-
fluence on treatment satisfaction, disease problems and 
quality of life. Patients treated with biological drugs for 
12 months showed the highest treatment satisfaction and 
the lowest Dermatology Life Quality Index score. A num-
ber of patients with topical treatment reported low qua-
lity of life, severe or very severe disease problems, and 
low treatment satisfaction. Some patients with psoriasis 
may be under-treated and might benefit from a more 
aggressive treatment strategy. It is important, however, 
that resource utilization is optimized and patients are not 
treated with more advanced agents than necessary. Key 
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Psoriasis is a chronic immune-mediated disease that 
appears on the skin. It can occur at any age in both men 
and women and affects approximately 3% of the popu-
lations in the Nordic countries (1). Psoriasis has been 
shown significantly to influence patients’ health-related 
quality of life (HRQoL) (2). As yet, there is no cure for 
psoriasis, but a range of topical, systemic and ultraviolet 
light-based treatments are available that can control and 
temporarily eliminate the symptoms of the disease. In 
recent years several new treatment options of systemic 
agents have been introduced for patients with psoriasis. 
For example, a number of biological drugs are now avail-
able as a complement or a substitute for traditional sys-
temic treatment. The total healthcare costs for treatment 
of severe psoriasis with biological drugs are significantly 
greater than with other systemic therapy (3). However, 
some of these costs are offset by substantial reductions in 
inpatient care and light-treatment and result in improved 
patient outcome. It is therefore important that biological 
drugs are provided only for those patients who really need 
this type of treatment and who will benefit most. One 
important issue from a health-economic perspective is 
how different aspects related to quality of life (QoL) and 
patient experience are associated with treatment pattern. 
According to treatment guidelines, the indications for 
treatment with biological drugs are similar in Denmark, 
Finland and Sweden. These drugs should be given to 
patients with moderate-to-severe psoriasis who have not 
responded to other systemic treatment or light treatment, 
or have a contraindication for such treatments (4–6).
The aim of the present study was to examine HRQoL, 
experience of severity of psoriasis-related problems, 
and treatment satisfaction in patients with psoriasis in 
Denmark, Finland and Sweden, and to analyse how 
these factors vary across different treatment groups.
MATERIALS AND METHODS
The study is based on 12 months’ data from patient surveys and 
retrospective medical chart reviews performed in Denmark, 
Finland and Sweden. Inclusion criteria were patients with pla-
que psoriasis, patients with both plaque psoriasis and psoriasis 
arthritis, a signed informed consent, and age between 18 and 75 
years. The only exclusion criterion was patients who participated 
in a clinical trial at the time of the study. Patients were identified 
from local registers in each clinic if they had the diagnosis code 
of psoriasis. All patients who had been treated at the clinic during 
a specified period were identified and consecutively selected 
backwards until a specified number of patients for each country 
had been identified. The patient survey with questions covering 
a 12-month period was then sent to the identified patients. For 
those who answered the survey and gave their informed consent 
to participate, additional data for the same 12-month period were 
collected from patient records by the participating physicians. 
Permission to perform the study was obtained from ethics com-
mittees in Finland and Sweden, but was not necessary in Denmark 
because it was classified as a non-biomedicine study. 
The patient survey included questions about treatments, pre-
sent state of health, presence of psoriasis problems, severity of 
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problems, problems with present treatment, treatment satisfac-
tion and two QoL instruments, the generic EuroQol (EQ-5D) 
and the dermatology-specific Dermatology Life Quality Index 
(DLQI). The chart review performed by a physician from each 
participating centre covered information about patient charac-
teristics and treatment. 
The time for the data collection differed between the 3 
countries, with the Swedish study performed in the third quarter 
of 2008, the Finnish study in the first quarter of 2009, and the 
Danish in the third quarter of 2010. Six dermatology clinics, 3 
Danish, 1 Finnish and 2 Swedish centres, participated. Some 
results from the Finnish and Swedish investigations have been 
reported previously, as well as details about the methods for 
data collection (7). The number of included patients was rather 
few in some treatment groups and the distribution of patients 
across the interventions differed between the 3 countries. For 
the present analyses the data from the 3 countries were pooled 
to provide reasonable subgroup samples and offer possibilities 
to investigate the potential influence of treatment pattern.
For analysis of treatment patterns, the following 3 groups were 
identified: topical treatment including emollients and topical cor-
ticosteroids; systemic drugs and/or biological drugs for less than 
12 months; and biological drugs for the whole 12-month period. 
Patients treated with topical corticosteroids could also have 
been treated with emollients and vitamin D analogues, and 
patients treated in any of the groups with systemic and/or 
biological drugs could also have used emollients and topical 
corticosteroids. Patients could even have been prescribed dif-
ferent types of light treatment and/or climate therapy.
Statistical analyses
In comparisons, Mann-Whitney U tests were used for dichoto-
mous or dummy variables, and t-tests were used for quantitative 
variables. To test for a relationship between EQ-5D and DLQI, 
data were analysed using Pearson’s correlation coefficient. 
Tests were two-sided.
Multiple regression analyses were performed to identify 
factors that have an influence on, or could best explain, the 
dependent variables treatment satisfaction and QoL scores 
measured with DLQI and EQ-5D. A significance level of 5% 
was used, together with maintaining the adjusted R2 as criteria 
for selection of variables that could best explain changes in the 
dependent variable. Dummy variables were coded 1 where a 
condition was present and 0 for all other values.
RESULTS
In total, 404 responding patients were included in the 
analyses, 131 from Denmark, 110 from Finland and 163 
from Sweden. The response rate in the patient survey 
was 57%, varying from 53% in Sweden to 65% in 
Denmark. Patient characteristics are shown in Table I. 
The patient populations from the 3 countries were 
similar regarding age and sex distribution. Danish pa-
tients have had their psoriasis diagnosis slightly longer 
than both Finnish and Swedish patients. In addition, the 
proportion of Danish patients with both plaque psoriasis 
and psoriasis arthritis was significantly higher (33%) 
than in Finland (18%) and Sweden (11%). The reported 
frequency of other chronic diseases was significantly 
lower among Swedish than among Finnish or Danish 
patients. Cardiovascular disease was the most common 
chronic comorbidity in all 3 countries. 
Patients in Denmark were, to a higher degree, treated 
with biological drugs compared with Finnish and Swedish 
patients, while topical treatment was the most common 
treatment among Finnish and Swedish patients. The 
distribution of the different treatment groups is shown in 
Table II. In Denmark only 1% of patients were treated with 
emollients only, while 10% in Finland and 23% in Sweden 
had received this single drug treatment (data not shown). 
In Denmark 45% had received biological drugs during the 
whole 12-month period, while in Finland and Sweden 4% 
and 6% had received such treatment, respectively.
Patients who had received light treatment were less 
frequent in Denmark, where only 11% had received such 
treatment during the last 12 months in comparison with 
44% in Finland and 45% in Sweden. Climate therapy 
was slightly more common in Denmark, where 8% had 
received this type of treatment compared with 3% in 
Finland and 1% in Sweden (data not shown).
The highest treatment satisfaction, 8.2 on a scale on 
which 0 represented not at all satisfied and 10 very sa-
tisfied, was found in patients who had been treated with 
biological drugs for 12 months. In this group the highest 
frequency (75%) of experience of no or mild psoriasis 
problems was found (Fig. 1). Moderate disease-related 
problems were most common in patients who had 
received topical treatment only (36%) and in patients 
who had been treated with non-biological systemic 
agents and/or biological drugs for less than 12 months 
(37%). Both these groups reported severe or very severe 
problems in 19% compared with 4% of patients treated 
with biological drugs for 12 months.









(n = 404) p-value
Male, n (%) 85 (65) 65 (59) 108 (66) 258 (64) n.s.a,b,c
Age, years, mean (range) 50 (19–77) 53 (26–75) 51 (22–76) 51 (19–77) n.s.a,b,c
Time since diagnosis, years, mean (range) 23 (1–70) 20 (2–65) 18 (2–71) 20 (1–71) p < 0.05a,b, n.s.c 
Plaque psoriasis, n (%) 87 (66) 89 (82) 145 (89) 321 (79)
Plaque psoriasis+psoriasis arthritis, n (%) 43 (33) 19 (18) 18 (11) 80 (20) p < 0.05a,b, n.s.c
Other chronic diseases, n (%)d 60 (46) 61 (55) 58 (36) 179 (44) n.s.a,b, p < 0.05c
Cardiovascular disease, n (%) 29 (22) 42 (38) 22 (13) 93 (23) p < 0.05a,c, n.s.b
aDifference between Denmark and Finland; bDifference between Denmark and Sweden; cDifference between Finland and Sweden. dOther chronic diseases 
were cardiovascular disease, malignant disease, collagenosis or other joint disease, asthma or chronic obstructive lung disease, diabetes, kidney disease, or 
other chronic disease (not specified). Difference between groups: n.s.: non-significant.
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The lowest mean score, 0.74 measured with EQ-
5D, was found in patients treated with non-biological 
systemic agents and/or biological drugs for less than 
12 months (Fig. 2). However, there was no statistically 
significant difference in EQ-5D scores between the 3 
treatment groups. For patients treated with biological 
drugs during the whole 12-month period the mean DLQI 
score was 3.2 (Fig. 2). This figure was statistically signi-
ficant in comparison with the other 2 groups (p < 0.000).
There was a statistically significant negative correla-
tion (–0.503; p = 0.01) between the EQ-5D score and the 
DLQI score; thus, the higher impact the disease has on the 
patient’s life (DLQI), the lower the EQ-5D value (Fig. 3).
The results from the regression analyses or identi-
fication of variables that have an influence on or can 
explain treatment satisfaction and QoL scores measured 
by DLQI and EQ-5D are shown in Table SI (available 
from http://www.medicaljournals.se/acta/content/?d
oi=10.2340/00015555-1485). In the 3 regression mo-
dels, severe or very severe disease was a statistically 
significant factor. Treatment with biological drugs for 12 
months was statistically significant regarding changes 
in values for treatment satisfaction and DLQI scores, 
but not for changes in EQ-5D scores. Disease severity 
and presence of co-morbidity were factors that had a 
statistically significant influence on EQ-5D scores as 
well as treatment satisfaction and presence of psoriasis 
arthritis.
DISCUSSION
The most important findings from the present study are 
that patient satisfaction and QoL measured with the 
dermatology-specific instrument DLQI are related to 
the type of treatment the patients have received. 
The results also show that treatment patterns differed 
between the 3 Nordic patient populations. A possible 
explanation for the more frequent use of biological 
drugs in the Danish study population is that psoriasis 
arthritis was more common than in the Finnish and 
Swedish populations. Another possible explanation for 
the different treatment patterns in the 3 countries could 
be related to the organization of psoriasis treatment, 
drug financing and local budget restrictions that limit 
the actual choice of treatments. 
The strength of the present study is that the data col-
lection, with patient questionnaires and review of patient 
records, was performed in a similar way in 3 Nordic 
Table II. Treatment pattern of psoriasis for 12-month period 
Treatment group
Denmark 
(n = 131) 
n (%)
Finland 
(n = 110) 
n (%)
Sweden 
(n = 163) 
n (%)
All patients 
(n = 404) 
n (%)
Topical treatment 21 (16) 60 (54) 104 (64) 185 (46)
Systemic (not biological), systemic & biological < 12 months, or biological < 12 months 51 (38) 46 (42) 49 (31) 146 (36)
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Severe or very severe problems 
Treatment satisfaction (0–10) 
Fig. 1. Psoriasis-related problems rated by patients and mean estimated 
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Fig. 2. Mean health-related quality of life scores in different treatment groups 






























Severe or very severe 
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Fig. 3. Mean EuroQol (EQ-5D) and Dermatology Life Quality Index (DLQI) 
scores in relation to disease problems rated by patients (n = 386). Missing 
values from 18 patients.
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countries. A limitation might be that the data collection 
was not completed at the same time in all countries. 
In all 3 participating countries a majority of men were 
included. This corresponds to both the Danish and the 
Swedish annual register reports, which show that more 
men were treated with biological drugs and by spe-
cialists in dermatology (4, 8). It also corresponds with 
previous studies, which have reported similar patterns 
(9, 10). In addition, the age distribution in the present 
study corresponds with the reports from the registers. 
We therefore believe that the included patients are re-
presentative for psoriasis patients treated in specialist 
centres in Nordic countries.
In the present study patients with more extensive 
psoriasis problems had lower QoL, measured as lower 
EQ-5D values and higher DLQI scores. Treatment satis-
faction varied across treatment groups. Patients treated 
with biological drugs during the whole 12-month period 
were more satisfied with their treatment, experienced 
fewer psoriasis-related problems and experienced less 
severe problems.
The dermatology-specific instrument DLQI appears 
to be more appropriate than the generic instrument 
EQ-5D to detect differences in QoL between psoriasis 
patients in different treatment groups. However, DLQI 
scores cannot be used for calculation of quality adjusted 
life years (QALYs), which is an essential outcome 
measure in health-economic evaluations. It is therefore 
suggested that both instruments are included in clinical 
studies to evaluate the cost-effectiveness of different 
treatment options, especially when new treatment al-
ternatives are introduced.
In addition, QoL measurements may be a useful tool 
in clinical practice to be able to improve treatment for 
individual patients and to optimize resource utilization.
In conclusion, some patients treated with topical 
treatment reported low QoL, were dissatisfied with 
their treatments, and experienced severe problems due 
to their psoriasis. For selected patients in this group the 
condition could probably be improved by more effective 
treatment. The future challenge of financing healthcare 
and the introduction of new more expensive drugs may 
increase demands for more cost-effective treatment op-
tions. This could optimize individual treatment choice 
and contribute to improved QoL, especially among 
those patients who are currently not treated efficiently 
due to under-treatment, or might reduce costs among 
patients who are currently treated with unnecessary 
advanced therapies.
ACkNOWLEDGEMENTS
Financial support: The study was funded by janssen-Cilag. 
Conflicts of interest: CH was at the time of conducting this 
study an employee of IHE and is currently an employee of 
janssen-Cilag; RG, Investigator/speaker and/or consultant for 
Abbott, Almirall, Amgen, janssen-Cilag, MSD, Pfizer; kk, 
Investigator/speaker and/or consultant for Abbott, Almirall, 
Amgen, janssen-Cilag, LEO Pharma, MSD, Pfizer; IMM, PhD 
student partly financed by LEO Pharma.
REFERENCES
1. Naldi L. Epidemiology of psoriasis. Curr Drug Targets In-
flamm Allergy 2004; 3: 121–128.
2. de korte j, Sprangers M, Mombers F, Bos j. Quality of life 
in patients with psoriasis: a systematic literature review. j 
Invest Dermatol 2004; 9: 140–147.
3. Fonia A, jackson k, LeReun C, Grant DM, Barker jNWN, 
Smith CH. A retrospective cohort study of the impact of 
biologic therapy initiation on medical resource use and costs 
in patients with moderate to severe psoriasis. Br j Dermatol 
2010; 163: 807–816.
4. Dermbio. Årsrapport 2008. Annual report for the Danish 
database initiative for biological treatment of psoriasis in 
Denmark. 2008 [accessed 29 December, 2011]. Available 
from: https://dermbio.dk/formidling/Dermbio%20Aarsrap-
port%202008%20Final.pdf/view.
5. Läkemedelsverket [Medical Products Agency]. [Treatment 
of psoriasis – treatment guidelines]. Information from Lä-
kemedelsverket 2006; 5: 5–16 (in Swedish).
6. The Finnish Medical Society Duodecim. [Current care 
guideline on psoriasis and psoriatic arthritis.] Duodecim 
2008; 124: 324–346 (in Finnish).
7. Hjortsberg C, Bergman A, Bjarnason A, Heikkilä H, Hjelm-
gren j, Svensson A, Tennvall GR. Are treatment satisfaction, 
quality of life, and self-assessed disease severity relevant 
parameters for patient registries? Experiences from Finnish 
and Swedish patients with psoriasis. Acta Derm Venereol 
2011; 91: 409–414.
8. Schmitt-Egenolf M. (PsoReg, Register for systemic treat-
ment of psoriasis. Annual report for September 2007 – Au-
gust 2008]. PsoReg, Umeå University, 2008 (in Swedish).
9. Flytström I, Stenberg B, Svensson Å, Bergbrant I-M. 
Methotrexate vs. ciclosporin in psoriasis: effectiveness, 
quality of life and safety. A randomized controlled trial. Br 
j Dermatol 2007; 158: 116–121.
10. Nyberg F, Osika I, Evengård B. “The laundry bag project” 
– unequal distribution of dermatological healthcare resour-
ces for male and female psoriatic patients in Sweden. Int j 
Dermatol 2008; 47: 144–149.
Acta Derm Venereol 93
